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A report on the American Association for Cancer Research
Conference ‘Advances in Proteomics in Cancer Research’,
Amelia Island, USA, 27 February-2 March 2007.
Cancer seems to have afflicted humans throughout recorded
history. The earliest descriptions are in Egyptian papyri
written between 3000 and 1500 BC. Cancer was named,
some 2,400 years ago, after the Greek word karkinos, a crab,
which Hippocrates thought a tumor resembled. More than
two millennia later, cancer remains among the leading
causes of death in industrialized countries. The name cancer
covers an extremely heterogeneous set of diseases with
different pathologies, prognosis and treatments. In many
cases, histological or molecular standards for diagnosis and
categorization are missing. An American Association for
Cancer Research conference in February brought together
experts covering diverse facets of proteomics and cancer
research with the aim of reviewing progress in the quest for
new cancer biomarkers.
Raymond DuBois (Vanderbilt-Ingram Cancer Center,
Nashville, USA) opened the conference with a keynote
address in which he emphasized the critical importance of
early detection in cancer control and prevention. Most
cancer can be effectively treated if detected early. The
identification of unique molecular signatures in developing
cancers is expected to pave the way toward more tailored
and personalized treatments.
Plasma as a source of cancer biomarkers
Blood plasma has attracted great attention as a potential
source of protein biomarkers. It is readily accessible through
minimally invasive methods and, most importantly, it
circulates through virtually all tissues. Current efforts
profiling human plasma proteomes are motivated by two
assumptions. First, the state of a tissue and its progression
towards disease are reflected in its protein content. Second,
these tissue-specific markers can be efficiently detected in
the plasma. Gilbert Omenn (University of Michigan, Ann
Arbor, USA) presented an update from the Human
Proteome Organization (HUPO) Plasma Proteome Project. It
now covers more than 3,020 non-redundant gene products,
corresponding to more than 7,000 proteins or isoforms.
Interestingly, besides the proteins that are primarily active
in the plasma, many of the proteins found in plasma were
released into the circulation by organs and cells throughout
the body. The current dataset already represents an invaluable
source of information, but Omenn believes that further
progress will entail the integration of new approaches. The
quantification of proteins in plasma remains a challenging
enterprise because of the complexity of these samples and
their extreme dynamic range, covering more than ten orders
of magnitude of concentrations. The most interesting
proteins, the ones originating from tissues or tumors, are
expected to be present at extremely low concentration.
The next phase of the HUPO Plasma Proteome Project
includes cross-analysis of the original sources of biomarkers:
the different organs, tumors and more proximal biofluids
(tears, urine and saliva). Along those lines, Julio Celis
(Danish Cancer Society, Copenhagen, Denmark) presented a
remarkable proteomics profiling of breast apocrine cystic
lesions that led to the successful identification of two
proteins differentially expressed in these lesions, 15-
hydroxyprostaglandin dehydrogenase and 3-hydroxymethyl-
glutaryl-CoA reductase.
Complementary to the current ‘scanning’ or shotgun
approaches that aim at detecting all proteins in the plasma,
new strategies are gaining momentum that rely on the
optimized, quantitative detection of pre-selected analytes
using targeted mass spectrometry (MS). For this type of
approach, Bruno Domon (Institute of Molecular Systems
Biology, ETH Zurich, Switzerland) proposed a two-stepstrategy, further demonstrated by Ruedi Aebersold (also at
the Institute for Molecular Systems Biology), that alleviates
some of the current limitations. The first step consists of the
in-depth analysis of tissue and tumor samples using high-
performance instruments such as Fourier transform mass
spectrometers. The complexity of the samples is reduced and
their enrichment in low-abundance proteins is achieved by
fractionation procedures that specifically target glyco-
proteins - glycosylation is characteristic of cell-surface and
secreted proteins, which are the most likely to enter the
bloodstream. Using a hydrazide-based chemistry to
selectively enrich for N-linked glycopeptides by affinity
purification, a 20-fold reduction in sample complexity was
achieved. Many of the glycosylated proteins identified in
solid tissues could also readily be detected in the plasma,
confirming the general validity of the concept. In the second
step, Domon and Aebersold propose to specifically quantify
a pre-selected set of particularly interesting or discrimina-
ting tryptic peptides in plasma using targeted analytical MS
methods such as multiple reaction monitoring (MRM). In
contrast with the widely adopted scanning MS approaches
that aim at identifying all proteins in a sample, MRM relies
on the optimized quantitative detection of selected proteins
with increased sensitivity.
Daniela Dinulescu (Brigham and Women’s Hospital, Boston,
USA) described genetically engineered mouse models of
ovarian cancer that faithfully mimic the clinical disease. In
collaboration with Samir Hanash (Fred Hutchinson Cancer
Research Center, Seattle, USA), plasma derived from mice
that showed microscopic ovarian cancer lesions or meta-
stases was analyzed by a quantitative proteomics approach
called the intact protein analysis system (IPAS). This
combines protein labeling with Cy dyes, three-dimensional
protein separation based on charge, hydrophobicity and
molecular mass, and protein identification by shotgun
methods. As well as proteins already described in ovarian
tumors, which validated the general strategy, Dinulescu
reported a shortlist of 20 new candidate biomarkers that are
currently being validated in patients with ovarian cancer.
Profiling of tissues and tumors
The molecular profiling of human biopsies is frequently
complicated by their inherent biological heterogeneity.
Methods based on the profiling of proteins across tissues or
tumor sections give useful clues to the spatial distributions
of the candidate markers, but these methods have in the past
been limited by the lack of specific affinity reagents.
Matthias Uhlen (Royal Institute of Technology, Stockholm,
Sweden) presented an antibody-based proteomics approach
that aims at the production of specific affinity agents for all
human proteins. So far, more than 1,500 antibodies have
been produced and used to profile proteins across 48 human
tissues, 20 different cancers and 46 cell lines. The resulting
Human Protein Atlas (http://www.proteinatlas.org) provides
more than one million high-resolution images annotated by
pathologists.
Classic visualization or proteomic strategies usually fail to
directly inform on the activation state of proteins. To
address this point, Roger Tsien (University of California San
Diego, La Jolla, USA) has synthesized a novel series of
imaging agents based on activatable cell-penetrating
peptides, which are specifically designed to visualize matrix
metalloprotease activity in vivo. The peptides consist of a
polyanion (nine glutamate residues), an MMP-specific
cleavable linker and a polycation (nine arginine residues),
linked to the fluorescent dye Cy5. The complete peptide is
impermeable to cell membranes, but on cleavage of the
polyanion by MMP, the resulting Arg9-Cy5 is readily taken
up by neighboring cells, where fluorescence accumulates.
Tsien described the successful use of the activatable cell-
penetrating peptides to visualize the activity of matrix
metalloproteases around tumors in several xenografted and
genetically engineered mouse models of cancer. The general
method holds great promise not only for the diagnosis of
cancerous lesions, but also for the specific delivery of toxic
chemotherapeutic agents to tumors.
Mass spectrometry is also taking center stage in direct
imaging. Richard Caprioli (Vanderbilt University Medical
Center, Nashville, USA) reported recent applications in
imaging mass spectrometry, which is based on matrix-
assisted laser desorption/ionization mass spectrometry
(MALDI-MS), directly on frozen sectioned tissues or tumors.
Caprioli showed that the protein patterns obtained could be
correlated with lung tumor classification and with patient
survival trends. He also presented some interesting
developments that aim at integrating histology with the
mass spectrometry profiles. These included the selection of
tissue-staining procedures compatible with mass
spectrometry and the use of conductive glass slides for
microscopy that also serve as target plates for MALDI-MS.
Charting and quantifying changes in protein
phosphorylation
Cell signaling is often mediated by post-translational
modifications that modify protein conformation, localiza-
tion, activity and stability. Generally, the deregulation of
these processes leads to disease, including cancer. After
decades of ‘one by one’ studies, systems-wide analyses are
now being attempted.
Donald Hunt (University of Virginia, Charlottesville, USA)
presented a new peptide fragmentation strategy adapted to
the mass-spectrometric study of post-translational modifica-
tions. Traditionally, the peptide backbone is fragmented
during the MS procedure to determine the amino-acid
sequence and deduce potential sites of modification. The
efficiency of the fragmentation, however, is often dependent
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modifications. Hunt coupled the electron transfer dissocia-
tion (ETD) of peptides to a second ion/ion reaction, the
proton transfer charge reduction (PTR), designed to reduce
charge complexity. The ETD-PTR method not only circum-
vents the traditional restrictions associated with peptide
fragmentation but also preserves the phosphoryl group on
phosphoserine and phosphothreonine residues. Hunt
demonstrated the method with the global analysis of protein
phosphorylation in a model eukaryote, Saccharomyces
cerevisiae; more than 1,200 phosphorylation sites were
identified on 629 proteins.
Integrated strategies aimed at charting the temporal
dynamics of protein phosphorylation on the scale of entire
proteomes were presented by Matthias Mann (Max-Planck-
Institute for Biochemistry, Martinsried, Germany). These
combine quantitative methods, such as stable-isotope
labeling by amino acids in cell culture (SILAC), with the
specific enrichment of phosphopeptides by strong-cation
chromatography or titanium oxide. Mann reported the most
comprehensive time-resolved changes determined so far in
the phosphoproteome in HeLa cells following stimulation
with epidermal growth factor (EGF). He presented ongoing
work aimed at charting the cross-talk between EGF and
tumor necrosis factor-α. Last but not least, the approach
holds great promise for the charting of the effects or mode of
action of kinase inhibitors.
In conclusion, the conference provided a comprehensive
update on the emerging approaches and methods in the field
of proteomics that are channeling the current quest for new
cancer biomarkers. These new developments put us well on
the way towards the comprehensive profiling of proteins in
tumors and healthy organs. It may not be long before the
identification of unique molecular patterns or signatures in
developing cancers opens the way to more tailored and
personalized treatments.
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